688046 药康生物
已收盘 05-15 15:00:01
资讯
新帖
简况
药康生物（688046）披露2022年限制性股票激励计划首次授予部分第三个归属期符合归属条件的公告，5月14日股价上涨1.52%
证券之星 · 05-14 18:37
药康生物（688046）披露2022年限制性股票激励计划首次授予部分第三个归属期符合归属条件的公告，5月14日股价上涨1.52%
药康生物（688046）披露保荐总结报告书，5月13日股价下跌2.11%
证券之星 · 05-13 18:07
药康生物（688046）披露保荐总结报告书，5月13日股价下跌2.11%
5月11日药康生物涨6.45%，天弘医药创新A基金重仓该股
证券之星 · 05-11
5月11日药康生物涨6.45%，天弘医药创新A基金重仓该股
药康生物涨6.45%，中邮证券一个月前给出“买入”评级
证券之星 · 05-11
药康生物涨6.45%，中邮证券一个月前给出“买入”评级
药康生物（688046）披露2025年年度股东会会议资料，5月6日股价下跌1.16%
证券之星 · 05-06
药康生物（688046）披露2025年年度股东会会议资料，5月6日股价下跌1.16%
【机构调研记录】财信基金调研欧普照明、药康生物
证券之星 · 04-28
【机构调研记录】财信基金调研欧普照明、药康生物
【机构调研记录】国海富兰克林基金调研金盘科技、药康生物等3只个股（附名单）
证券之星 · 04-28
【机构调研记录】国海富兰克林基金调研金盘科技、药康生物等3只个股（附名单）
【机构调研记录】前海联合调研药康生物
证券之星 · 04-28
【机构调研记录】前海联合调研药康生物
药康生物（688046）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 04-24
药康生物（688046）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
药康生物(688046.SH)发布一季度业绩，归母净利润4710万元，同比增长57.12%
智通财经 · 04-23
药康生物(688046.SH)发布一季度业绩，归母净利润4710万元，同比增长57.12%
药康生物（688046）披露2025年度利润分配预案，4月22日股价上涨0.72%
证券之星 · 04-22
药康生物（688046）披露2025年度利润分配预案，4月22日股价上涨0.72%
4月7日药康生物涨9.28%，天弘医疗健康混合A基金重仓该股
证券之星 · 04-07
4月7日药康生物涨9.28%，天弘医疗健康混合A基金重仓该股
每周股票复盘：药康生物（688046）2025年净利增31.49%
证券之星 · 02-08
每周股票复盘：药康生物（688046）2025年净利增31.49%
药康生物（688046）披露2025年度业绩快报公告，2月3日股价上涨3.16%
证券之星 · 02-03
药康生物（688046）披露2025年度业绩快报公告，2月3日股价上涨3.16%
药康生物(688046.SH)2025年度归母净利润1.44亿元，同比增长31.49%
智通财经 · 02-03
药康生物(688046.SH)2025年度归母净利润1.44亿元，同比增长31.49%
药康生物跌4.07% 2022年上市募资11亿元
中金财经 · 01-19
药康生物跌4.07% 2022年上市募资11亿元
药康生物（688046）披露关于参股公司回购公司所持股份暨关联交易的公告，1月7日股价上涨3.04%
证券之星 · 01-07
药康生物（688046）披露关于参股公司回购公司所持股份暨关联交易的公告，1月7日股价上涨3.04%
专职研发人员降至5人，百奥赛图估值靠什么支撑？
投资时报 · 2025-12-01
专职研发人员降至5人，百奥赛图估值靠什么支撑？
每周股票复盘：药康生物（688046）拟每10股派0.30元
证券之星 · 2025-11-16
每周股票复盘：药康生物（688046）拟每10股派0.30元
药康生物大跌5% 近半年4家券商买入
智选洞察 · 2025-03-10
药康生物大跌5% 近半年4家券商买入
公司概况
公司名称：
江苏集萃药康生物科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-04-25
主营业务：
江苏集萃药康生物科技股份有限公司的主营业务是实验动物模型的研发创制、生产销售及相关技术服务。公司的主要产品是商品化小鼠模型、功能药效、定制繁育、模型创制、代理进出口及其他。
发行价格：
22.53
{"stockData":{"symbol":"688046","market":"SH","secType":"STK","nameCN":"药康生物","latestPrice":21.51,"timestamp":1778828401000,"preClose":20.76,"halted":0,"volume":6876653,"delay":0,"changeRate":0.0361,"floatShares":409999999,"shares":409999999,"eps":0.3897,"marketStatus":"已收盘","change":0.75,"latestTime":"05-15 15:00:01","open":20.76,"high":21.99,"low":20.72,"amount":148000000,"amplitude":0.0612,"askPrice":21.53,"askSize":2,"bidPrice":21.51,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.3897,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":20.76,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":22.84,"lowLimit":18.68,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":410000000,"isCdr":false,"pbRate":3.87,"roa":"--","peRate":55.196305,"roe":"2.09%","epsLYR":0.35,"committee":0.182906,"marketValue":8819000000,"turnoverRate":0.0168,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-18。","afterMarket":{"amount":0,"volume":0,"close":21.51,"buyVolume":0,"sellVolume":0,"time":1778830437559,"indexStatus":"已收盘 05-15 15:30:00","preClose":20.76},"floatMarketCap":8819000000},"requestUrl":"/m/hq/s/688046/wiki","defaultTab":"wiki","newsList":[{"id":"2635716311","title":"药康生物（688046）披露2022年限制性股票激励计划首次授予部分第三个归属期符合归属条件的公告，5月14日股价上涨1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635716311","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635716311?lang=zh_cn&edition=full","pubTime":"2026-05-14 18:37","pubTimestamp":1778755032,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，药康生物报收于20.76元，较前一交易日上涨1.52%，最新总市值为85.12亿元。该股当日开盘20.44元，最高21.17元，最低20.35元，成交额达1.22亿元，换手率为1.43%。公告显示，公司2022年限制性股票激励计划首次授予部分第三个归属期归属条件已成就。本次拟归属限制性股票数量为24.44万股，归属人数为13人，股票来源为公司向激励对象定向发行A股普通股。归属价格为14.63元/股。激励对象个人绩效考核均达标，可归属比例为100%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400035318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278865","title":"药康生物（688046）披露保荐总结报告书，5月13日股价下跌2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278865","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635278865?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:07","pubTimestamp":1778666831,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，药康生物报收于20.45元，较前一交易日下跌2.11%，最新总市值为83.84亿元。该股当日开盘20.58元，最高20.73元，最低20.12元，成交额达9308.98万元，换手率为1.11%。公司于近日披露《华泰联合证券有限责任公司关于江苏集萃药康生物科技股份有限公司首次公开发行股票并在科创板上市之保荐总结报告书》。截至2025年12月31日，募集资金尚未使用完毕，保荐机构将继续履行持续督导责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409396","title":"5月11日药康生物涨6.45%，天弘医药创新A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409396?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:28","pubTimestamp":1778488113,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日药康生物涨6.45%创60日新高，收盘报21.8元，换手率2.05%，成交量8.41万手，成交额1.78亿元。重仓药康生物的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为25.81。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为天弘基金的天弘医药创新A。天弘医药创新A目前规模为5.71亿元，最新净值1.0214，较上一交易日下跌1.84%，近一年上涨28.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","09939","BK1161","159938","BK1515","BK0216","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634350409","title":"药康生物涨6.45%，中邮证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634350409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634350409?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:28","pubTimestamp":1778488103,"startTime":"0","endTime":"0","summary":"今日药康生物涨6.45%，收盘报21.8元。2026年3月20日，中邮证券研究员盛丽华,徐智敏发布了对药康生物的研报《主业增速稳健，国际化与创新战略成果持续兑现》，该研报对药康生物给出“买入”评级。公司为动物模型国内领先者，凭借基因编辑模型的高壁垒持续拓展海外市场和创新业务，首次覆盖，给予“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国信证券的陈曦炳、彭思宇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633189551","title":"药康生物（688046）披露2025年年度股东会会议资料，5月6日股价下跌1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633189551","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633189551?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:17","pubTimestamp":1778062637,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，药康生物报收于20.36元，较前一交易日下跌1.16%，最新总市值为83.48亿元。该股当日开盘20.48元，最高20.54元，最低20.08元，成交额达1.4亿元，换手率为1.68%。近日，药康生物发布2025年年度股东会会议资料。公告显示，江苏集萃药康生物科技股份有限公司召开2025年年度股东会，审议2025年年度报告、董事会工作报告、财务决算报告、2026年财务预算、利润分配预案、续聘审计机构、董事薪酬、新增内部治理制度等议案，并听取独立董事述职报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600030545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630349752","title":"【机构调研记录】财信基金调研欧普照明、药康生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2630349752","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630349752?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:05","pubTimestamp":1777334752,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月27日披露的机构调研信息，财信基金近期对2家上市公司进行了调研，相关名单如下：1）欧普照明 调研纪要：公司2025年下半年营业收入暖，盈利水平稳定，毛利率达39.3%。财信基金成立于2024年，截至目前，资产管理规模4.79亿元，排名188/212；资产管理规模4.79亿元，排名156/212；管理公募基金数8只，排名157/212；旗下公募基金经理3人，排名160/212。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800026717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0224","688046","BK0141","603515","BK0020","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630349208","title":"【机构调研记录】国海富兰克林基金调研金盘科技、药康生物等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2630349208","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630349208?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:04","pubTimestamp":1777334697,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月27日披露的机构调研信息，国海富兰克林基金近期对3家上市公司进行了调研，相关名单如下：1）金盘科技 调研纪要：2026年第一季度，公司数据中心领域实现销售收入3.83亿元，同比增长103.77%；销售订单17.35亿元，同比增长278.45%；在手订单37.63亿元，同比增长116.66%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800026623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0224","BK0216","688676","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630349747","title":"【机构调研记录】前海联合调研药康生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2630349747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630349747?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:04","pubTimestamp":1777334679,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月27日披露的机构调研信息，前海联合近期对1家上市公司进行了调研，相关名单如下：1）药康生物 调研纪要：国内产能约29万笼，2026年4月达满产，广东二期18,000笼预计2026Q3投产；美国新总部2025年6月启用，产能5,000笼。旗下最近一年表现最佳的公募基金产品为前海联合泳隆混合A，最新单位净值为1.81，近一年增长93.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800026591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629840495","title":"药康生物（688046）2026年一季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2629840495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629840495?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:24","pubTimestamp":1777040666,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期药康生物发布2026年一季报。截至本报告期末，公司营业总收入2.08亿元，同比上升21.79%，归母净利润4710.38万元，同比上升57.12%。本报告期药康生物盈利能力上升，毛利率同比增幅1.6%，净利率同比增幅29.01%。去年的净利率为17.98%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400065064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629025412","title":"药康生物(688046.SH)发布一季度业绩，归母净利润4710万元，同比增长57.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629025412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629025412?lang=zh_cn&edition=full","pubTime":"2026-04-23 00:01","pubTimestamp":1776873667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药康生物(688046.SH)披露2026年第一季度报告，报告期公司实现营收2.08亿元，同比增长21.79%;归母净利润4710万元，同比增长57.12%;扣非净利润3881万元，同比增长54.58%。基本每股收益0.12元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629047047","title":"药康生物（688046）披露2025年度利润分配预案，4月22日股价上涨0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629047047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629047047?lang=zh_cn&edition=full","pubTime":"2026-04-22 22:16","pubTimestamp":1776867377,"startTime":"0","endTime":"0","summary":"截至2026年4月22日收盘，药康生物报收于19.54元，较前一交易日上涨0.72%，最新总市值为80.11亿元。近日，江苏集萃药康生物科技股份有限公司发布《关于公司2025年度利润分配预案的公告》。公告显示，公司2025年度实现归属于上市公司股东的净利润142,636,806.31元，母公司累计未分配利润390,648,678.58元。本次合计拟派发现金红利77,704,300.00元，加上中期已分配红利及股份回购金额，现金分红与回购合计占净利润比例为72.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200054443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625693329","title":"4月7日药康生物涨9.28%，天弘医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625693329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625693329?lang=zh_cn&edition=full","pubTime":"2026-04-07 16:19","pubTimestamp":1775549969,"startTime":"0","endTime":"0","summary":"证券之星消息，4月7日药康生物涨9.28%，收盘报17.55元，换手率3.89%，成交量15.95万手，成交额2.79亿元。重仓药康生物的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为23.65。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为天弘基金的天弘医疗健康混合A。天弘医疗健康混合A目前规模为2.28亿元，最新净值1.6727，较上一交易日下跌0.28%，近一年下跌6.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700021893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216","159760"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609140525","title":"每周股票复盘：药康生物（688046）2025年净利增31.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609140525","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609140525?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:08","pubTimestamp":1770487694,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，药康生物报收于17.4元，较上周的17.45元下跌0.29%。本周，药康生物2月4日盘中最高价报18.41元。本周关注点来自业绩披露要点：药康生物2025年归属净利润同比增长31.49%。公司公告汇总药康生物发布2025年度业绩快报，营业总收入79,325.46万元，同比增长15.49%；营业利润16,455.34万元，同比增长37.85%；归属于母公司所有者的净利润14,439.76万元，同比增长31.49%；扣除非经常性损益的净利润11,800.96万元，同比增长55.80%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608870682","title":"药康生物（688046）披露2025年度业绩快报公告，2月3日股价上涨3.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608870682","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608870682?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:53","pubTimestamp":1770130392,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，药康生物报收于17.32元，较前一交易日上涨3.16%，最新总市值为71.01亿元。该股当日开盘16.96元，最高17.4元，最低16.67元，成交额达8392.27万元，换手率为1.2%。近日，江苏集萃药康生物科技股份有限公司发布2025年度业绩快报，营业总收入79,325.46万元，同比增长15.49%；营业利润16,455.34万元，同比增长37.85%；归属于母公司所有者的净利润14,439.76万元，同比增长31.49%；扣除非经常性损益的净利润11,800.96万元，同比增长55.80%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300043542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608828396","title":"药康生物(688046.SH)2025年度归母净利润1.44亿元，同比增长31.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608828396","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608828396?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:38","pubTimestamp":1770104327,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药康生物 披露2025年度业绩快报，2025年度公司实现营业收入7.93亿元，同比增长15.49%;归属于母公司所有者的净利润1.44亿元，同比增长31.49%。报告期内，公司围绕国际化与创新两大核心战略，持续开拓海外市场，坚持高强度研发投入，保持技术与产品的行业领先地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药康生物(688046.SH)2025年度归母净利润1.44亿元，同比增长31.49%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604743181","title":"药康生物跌4.07% 2022年上市募资11亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604743181","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604743181?lang=zh_cn&edition=full","pubTime":"2026-01-19 17:09","pubTimestamp":1768813743,"startTime":"0","endTime":"0","summary":"中国经济网北京1月19日讯 药康生物 今日股价下跌，截至收盘，该股报18.14元，跌幅4.07%。 药康生物于2022年4月25日在上交所科创板上市，发行价格为22.53元/股，公开发行股票数量5000万股，保荐机构为华泰联合证券有限责任公司，保荐代表人为季李华、洪捷超。 药康生物首次公开发行股票的发行费用总额为1.00亿元，其中，保荐承销费8278.75万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260119/31953563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601801801","title":"药康生物（688046）披露关于参股公司回购公司所持股份暨关联交易的公告，1月7日股价上涨3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801801?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:26","pubTimestamp":1767795981,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，药康生物报收于16.94元，较前一交易日上涨3.04%，最新总市值为69.45亿元。近日，药康生物发布关于参股公司回购公司所持股份暨关联交易的公告。本次交易构成关联交易，已经公司董事会等相关会议审议通过，无需提交股东会审议，尚需各方完成内部审议程序后生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700038983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588983779","title":"专职研发人员降至5人，百奥赛图估值靠什么支撑？","url":"https://stock-news.laohu8.com/highlight/detail?id=2588983779","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588983779?lang=zh_cn&edition=full","pubTime":"2025-12-01 23:18","pubTimestamp":1764602280,"startTime":"0","endTime":"0","summary":"创新药研发投入较大叠加三年净利润累计亏损近10亿元，百奥赛图资金压力加剧“基因编辑第一股”——百奥赛图（北京）医药科技股份有限公司（下称百奥赛图，2315.HK）距离实现“H+A”两地上市 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251201/c672879464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688265","688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583651721","title":"每周股票复盘：药康生物（688046）拟每10股派0.30元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651721?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:08","pubTimestamp":1763237296,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，药康生物报收于18.38元，较上周的17.39元上涨5.69%。本周，药康生物11月14日盘中最高价报18.69元。本周关注点公司公告汇总：药康生物拟每10股派发现金红利0.30元（含税）。本次利润分配以扣除公司回购专用证券账户股份后的总股本408,970,000股为基数，合计派发现金红利12,269,100.00元（含税）。华泰联合证券对药康生物2025年半年度利润分配涉及的差异化分红事项出具核查意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688046","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518614582","title":"药康生物大跌5% 近半年4家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2518614582","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518614582?lang=zh_cn&edition=full","pubTime":"2025-03-10 13:07","pubTimestamp":1741583237,"startTime":"0","endTime":"0","summary":"03月10日，药康生物股价大幅下跌，截至13点07分，药康生物下跌5.03%，报14.72元/股，成交3957万元，换手率1.28%，振幅6.77%。此外，数据统计显示，近半年内4家券商给予买入建议。资金动向截止发稿，药康生物获得主力净流出576万元，其中超大单流出665万元，大单流入90万元。最新财报显示，今年三季报，药康生物实现营业收入5.10亿元，同比增长12.13%，净利润为9,821.44万元，同比减少16.57%，基本每股收益为0.24元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310130833abf23e72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310130833abf23e72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778890256494,"stockEarnings":[{"period":"1week","weight":0.0503},{"period":"1month","weight":0.1393},{"period":"3month","weight":0.2638},{"period":"6month","weight":0.1723},{"period":"1year","weight":0.8413},{"period":"ytd","weight":0.4004}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏集萃药康生物科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"9140人(较上一季度增加20.09%)","perCapita":"44857股","listingDate":"2022-04-25","address":"江苏省南京市浦口区江北新区学府路12号","registeredCapital":"41000万元","survey":" 江苏集萃药康生物科技股份有限公司的主营业务是实验动物模型的研发创制、生产销售及相关技术服务。公司的主要产品是商品化小鼠模型、功能药效、定制繁育、模型创制、代理进出口及其他。","listedPrice":22.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药康生物,688046,药康生物股票,药康生物股票老虎,药康生物股票老虎国际,药康生物行情,药康生物股票行情,药康生物股价,药康生物股市,药康生物股票价格,药康生物股票交易,药康生物股票购买,药康生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}